News and Trends 11 Jul 2023 Inhaled mRNA medicines redefine respiratory disease treatment By Carsten Rudolph, co-founder and CEO of Ethris Advancements in mRNA technology have led to the development of inhaled mRNA medicines, which hold tremendous potential for revolutionizing the treatment of respiratory diseases, an area with high unmet needs. However, the primary hurdle in its clinical application lies in the identification of a delivery system that […] July 11, 2023 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Best in Biotech 10 Jul 2023 Lung cancer research: five advancements over the past year Lung cancer is the second most common cancer worldwide, with more than 2.2 million new cases of lung cancer being reported in 2020. Survival rates depend on the stage of diagnosis, and, according to statistics from Cancer Research UK, in England, more than 55% of people with stage 1 lung cancer survive for five years […] July 10, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 10 Jul 2023 Existing cancer drug could be repurposed to fight certain aggressive cancers A team of scientists led by Nanyang Technological University, Singapore (NTU Singapore) has found that an existing cancer drug could be repurposed to target a subset of cancers that currently lack targeted treatment options and is often associated with poor outcomes.This subset of cancers makes up 15% of all cancers and is especially prevalent in […] July 10, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 10 Jul 2023 “Ready-to-use” enzymatically produced cell-free synthetic DNA in mRNA manufacturing By Ashish Dhir, PhD and Amy Walker, PhD, 4basebio The pace, efficacy and scalability with which the success of mRNA vaccines against COVID-19 was demonstrated opened endless possibilities for mRNA medicine in broad areas of infectious diseases, cancers, protein-encoding replacement therapies. The advantages of RNA medicine are obvious, with the ease and speed of design […] July 10, 2023 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 10 Jul 2023 Making an impact through targeting mRNA Biotech company Molecure develops small molecule therapies that can regulate RNA and underexplored protein targets for the treatment of incurable diseases, including cancer and fibrotic and inflammatory diseases. The company, which was named as one of our 10 biotech companies leading the charge in Poland, told Labiotech that its RNA platform finds small molecules that […] July 10, 2023 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 10 Jul 2023 Unleashing the potential: Optimizing mRNA for the discovery of transformative medicines By Dr. Alexander Zehnder, CEO, CureVac The success of mRNA vaccines in COVID-19 propelled the role of this new modality to the forefront of medicine. Not only are new prophylactic mRNA vaccines for various respiratory diseases advancing through clinical development, but mRNA medicines are now being developed in many wide-ranging applications, including cancer and rare […] July 10, 2023 - 8 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Opinion 10 Jul 2023 Five innovations to take RNA vaccines to the next level By Venkata Indurthi, PhD, chief scientific officer, Aldevron During the COVID-19 pandemic, the world turned to a previously unused vaccine technology to rapidly develop desperately needed vaccines, providing immunity to millions worldwide. These new vaccines made use of the body’s natural translational machinery, which turns mRNA encoding the SARS-Cov2 spike protein into an antigen that […] July 10, 2023 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 7 Jul 2023 The future of food: what’s behind the cell-cultured meat industry regulations? The first-ever lab-grown burger was created at Maastricht University in the Netherlands, and eaten at a news conference in London in 2013. While everyone who tried a bite had something different to say about the taste and texture of the meat, it was agreed that this could be the start of something big. The technology […] July 7, 2023 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2023 CytoMed Therapeutics receives US patent for CAR-Gamma Delta T-cell technology CytoMed Therapeutics Limited, a Singapore-based biopharma company focused on novel donor cell-based immunotherapies for the treatment of various cancers, has announced that its CAR-gamma delta T cell (CAR-γδ T cell) technology, which it has licensed from A*STAR, has been granted a patent by the US Patent and Trademark Office (USPTO). The patent covers technologies for […] July 7, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Podcast 7 Jul 2023Beyond Biotech podcast 53: Antibody-drug conjugates On the podcast this week, we have a conversation about antibody-drug conjugates with Pejvack Motlagh, who was recently announced as the chief medical officer at Mablink Bioscience. Mablink Bioscience Mablink Bioscience is a biotechnology company developing the next generation of an emerging class of cancer drugs, antibody-drug conjugates (ADCs). Mablink’s patented hydrophilic drug-linker technology, PSARLink, […] July 7, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2023 TolerogenixX expands trial and closes €12M financing TolerogenixX GmbH, a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases, has announced that its phase IIb study in renal transplant patients has received the green light to initiate the B arm of the study. This arm consists of patients receiving minimal immune suppression […] July 7, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2023 FDA approves Alzheimer’s treatment Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) supporting the traditional approval of LEQEMBI (lecanemab-irmb) 100 mg/mL injection for intravenous use. The decision makes LEQEMBI the first and only approved treatment shown to reduce the rate of disease progression […] July 7, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email